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Purpose: There is only one prior report associating mutations in BEST1 with a diagnosis of retinitis
pigmentosa (RP). The imaging studies presented in that report were more atypical of RP and shared
features of autosomal recessive bestrophinopathy and autosomal dominant vitreoretinochoroidopathy.
Here, we present a patient with a clinical phenotype consistent with classic features of RP.
Observations: The patient in this report was diagnosed with simplex RP based on clinically-evident bone
spicules with characteristic ERG and EOG ﬁndings. The patient had associated massive cystoid macular
edema which resolved following a short course of oral acetazolamide. Genetic testing revealed that the
patient carries a novel heterozygous deletion mutation in BEST1 which is not carried by either parent.
While this suggests BEST1 is causative, the patient also inherited heterozygous copies of several muta-
tions in other genes known to cause recessive retinal degenerative disease.
Conclusions and Importance: How some mutations in BEST1 associate with peripheral retinal degener-
ation phenotypes, while others manifest as macular degeneration phenotypes is currently unknown. We
speculate that RP due to BEST1 mutation requires mutations in other modiﬁer genes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mutations in the gene BEST1 (MIM 607854), which encodes the
protein Bestrophin-1 (Best1), are responsible for 5 clinically distinct
inherited retinopathies: Best vitelliform macular dystrophy
(BVMD), adult-onset vitelliform macular dystrophy (AVMD), auto-
somal recessive bestrophinopathy (ARB), autosomal dominant
vitreoretinochoroidopathy (ADVIRC), and retinitis pigmentosa (RP)
[1e7]. While mutations in BEST1 are widely accepted to cause
BVMD, AVMD, ARB, and ADVIRC, there has been only one prior
report of mutations in BEST1 causing RP [7]. The clinical images in
that paper shared phenotypic features of ARB and ADVIRC, causing.A. Dalvin), AbouChehade.
ohsu.edu (J. Chiang), helle.
ond@mayo.edu (R. Iezzi),
Inc. This is an open access article usome to question whether the subjects in the study have classic RP,
and thus, whether BEST1 can cause RP [8].
BEST1 encodes bestrophin 1 (Best1) a homo-oligomeric anion
channel that, within the eye, is exclusively expressed in retinal
pigment epithelial (RPE) cells, where it normally localizes to the
basolateral plasma membrane and plays a critical role in regulating
Ca2þ signaling [9e11]. BEST1 mutations are typically thought to be
disease-causing when they result in loss of anion-channel activity
[12,13]. Previous studies have shown that the ﬁrst ~174 amino acids
of Best1 are sufﬁcient to permit oligomerization and that the ﬁrst
~366 amino acids are sufﬁcient for both homo-oligomerization and
channel activity [14,15]. It has also been demonstrated that mis-
localization alone is not pathogenic [14].
Here, we present a patient with RP due to a deletion mutation in
BEST1, H422fsX431.
2. Case report
All patients discussed in this report provided written consent
for publication of personal information, including details fromnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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longstanding history of nyctalopia and constricted peripheral
vision was evaluated by the retina service at Mayo Clinic after
referral from a facility in Denmark. His best-corrected distance
visual acuity with the prescription 1.00 þ 1.25  93 in the right
eye and þ0.25 þ 1.00  100 in the left eye was 0.2 logMAR (20/32)
in both eyes. Intraocular pressures were 10 and 11 in the right and
left eyes, respectively. On slit lamp biomicroscopic exam he was
found to have prominent corneal nerves, trace posterior subcap-
sular cataract, trace to 1þ vitreous cell, massive cystoid macular
edema (CME), retinal vascular attenuation (more prominent in the
periphery) and extensive bone spicules in both eyes (Fig. 1). CME
was further demonstrated on optical coherence tomography
(OCT) imaging. While OCT revealed mild CME prior to referral
(Fig. 2A and B), there was clear progression by the time of ex-
amination at Mayo Clinic (Fig. 2C and D). The patient was advised
to try treatment with oral acetazolamide for CME, and after 2e3
weeks of treatment with sustained release acetazolamide 250 mg
BID (Diamox SR), his CME had nearly resolved (Fig. 2E and F),
resulting in visual acuities of 0.3 logMAR (20/40) in the right eye
and 0.15 logMAR (20/28) in the left eye. OCT angiography per-
formed at Mayo Clinic was notable for inner retinal microvascular
capillary loss and remodeling (Fig. 3).
Visual ﬁeld testing showed generalized constriction to within
20 in both eyes (Fig. 4). Full-ﬁeld scotopic Ganzfeld ERG testing
revealed attenuation of rod and cone responses with trace residualFig. 1. Optos ultra-wideﬁeld fundus photos of the right (A) and left (B) eyes demonstrate ex
eyes. More magniﬁed views of the bone spicules are shown in the insets. Montage color fun
bone spicules in both eyes.photopic cone responses at 3.0 cd-Sec/M2 and less attenuation of
photopic ﬂicker responses. Scotopic 0.2 cd-Sec/M2 ﬂicker showed
amplitudes of 1.4 and 0.74 mV with computed attenuation to
0.05 mV equal to 29.9 and 23.9 years, OD and OS, respectively, based
upon Berson's observation of exponential decay in this response
(Fig. 5). Normative data with ERG testing performed according to
International Society for Clinical Electrophysiology of Vision
(ISCEV) standards indicate that normal values range as follows: b-
wave amplitude 348.96e362.60 mV, b-wave implicit time
49.48e50.49 milliseconds, and a-wave amplitude 234.50
to 231.29 mV for a dark-adapted combined standard ﬂash; b-wave
amplitude 261.06e310.41 mV for a dark-adapted dimwhite light; b-
wave amplitude 138.82e141.94 mV for a light-adapted single ﬂash;
and implicit time 26.38e26.77 milliseconds for 30-Hz ﬂicker
[16,17]. EOG Arden ratios in both eyes were <1.5. For reference,
according to ISCEV standards, Arden ratios >2.0 are considered to
be normal; those <1.5 are abnormally low [18]. Based on the sum of
these data the diagnosis of simplex retinitis pigmentosa was
conﬁrmed.
Of note, the father was also examined and had central serous
chorioretinopathy, which is likely unrelated. The parents otherwise
had no clinically-evident ocular abnormalities.
Genetic testing was carried out by the University of Oregon,
Casey Eye Institute, Molecular Diagnostic Laboratory using a panel
of 131 retinal dystrophy genes. A heterozygous deletion of 9348
bases (61729891e61733239) from the BEST1 gene resulting in thetensive bone spicules and retinal vascular attenuation in the peripheral retina of both
dus photos of the right (C) and left (D) eyes further support the presence of extensive
Fig. 2. Optical coherence tomography (OCT) of the right (A) and left (B) eyes taken in Denmark demonstrates mild cystoid macular edema (CME) in both eyes and epiretinal
membrane with mild tractional retinoschisis in the left eye prior to the time of referral. OCT of the right (C) and left (D) eyes taken at Mayo Clinic demonstrates massive CME in both
eyes that has progressed since the patient was examined in Denmark. OCT of the right (E) and left (F) eyes taken back in Denmark demonstrates resolution of CME in both eyes after
2e3 weeks of treatment with sustained-release oral acetazolamide 250 mg BID.
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was unique to the proband and absent from both parents whowere
also tested using the same retinal dystrophy panel. The deletion
begins within exon 10 of the BEST1 gene and extends beyond exon
11 resulting in a frame shift causing deletion of 146aa from Best1,
and extending into the adjacent ferritin heavy chain (FTH) gene on
the opposite strand of DNA. The proband also carried heterozygous
mutations in the genes GUCA1A, GPR179, IQCB1, and TRIM32, four
genes implicated in other retinal degenerative diseases. These
mutations were not considered causative as they were carried by
the unaffected parents of the proband as well. It is likely that the
deletion from the FTH gene results in a single null allele for FTH.
However, at this point the proband has not exhibited any symptoms
of ferritin deﬁciency. Of note, both the father and the proband
underwent repeat genetic screening at Mayo Clinic using wholeexome sequencing, which conﬁrmed the ﬁndings from the Oregon
testing.3. Discussion and conclusions
Here we present a patient with a classic RP phenotype asso-
ciated with a mutation in BEST1. The prior report on RP due to
BEST1 mutation identiﬁed missense mutations, some of which
were also associated with BVMD, and the clinical phenotype of the
patients in that study is somewhat atypical for RP [7]. The patients
in the prior study have some clinical features consistent with ARB
or ADVIRC [7]. In the present report this subject has a classic
clinical phenotype consistent with a diagnosis of dominant RP.
The clinical and imaging ﬁndings in this report differ signiﬁcantly
from those previously reported for ARB [2,5,15,19,20]. ARB is a
Fig. 3. Optical coherence tomography angiography of the right (A and B) and left (C and D) eyes reveals inner retinal microvascular capillary loss and remodeling in
both eyes.
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alleles. While it is possible that we did not detect an intergenic
mutation in BEST1, we are unaware of any report of mutations in
non-coding regions of BEST1. The proband carries a single wild
type allele. From a clinical perspective, ARB affects primarily the
macula. Our patient exhibits what is primarily a peripheral retinal
dystrophy. All ARB patients exhibit a serous detachment of the
macula often with central yellow subretinal deposits, and small
yellow deposits ringing the central detachment. These were
notably absent in the case presented here [20]. Patients with ARB
report central vision loss as an initial symptom with a relatively
normal peripheral visual ﬁeld; in this case peripheral vision was
severely affected with central vision remaining intact [20]. Pa-
tients with ARB were also reported to be mildly to highly hyper-
opic; this patient was mildly myopic in the right eye with very
slight hyperopia in the left eye [20] While some patients with ARB
are reported to have multifocal atrophic lesions or RPE atrophy,
none were reported to have bone spicules, a deﬁning character-
istic of RP and a prominent feature of this case [20]. Similar to
patients with ARB, the patient in this case had an abnormal EOG.However, the ERG was abnormal as well, which can also be seen in
ARB [20].
Another possible diagnosis could be ADVIRC. Like RP, ADVIRC is
a peripheral retinopathy and is due to dominant mutations in
BEST1. However, the fundus in ADVIRC is characterized by well-
deﬁned circumferential zones of peripheral hyperpigmentation.
Like our proband, however, the ERG can be quite low, and the EOG
<1.5 in ADVIRC. Central vision in ADVIRC, when compromised, is
often compromised due to CME. The progression of ADVIRC, how-
ever, is typically very slow and visual ﬁelds are usually not as
constricted as in our subject.
The patient in this report also had near complete resolution of
his CME after a short course of oral acetazolamide. Carbonic
anhydrase inhibitors have a well-established role in managing
CME, speciﬁcally in RP patients [21]. The underlying mechanism of
action is thought to be related to carbonic anhydrase inhibitor-
driven acidiﬁcation of the subretinal space that directly results in
ﬂuid transport by RPE cells [22]. The excellent response of this
patient to acetazolamide further supports his classic RP presenta-
tion. However, response to acetazolamide is not speciﬁc to RP. In
Fig. 4. Visual ﬁeld testing (30-2, size V, FASTPAC) in the right (A) and left (B) eyes demonstrates constriction of the visual ﬁeld within 20 in both eyes. Testing was highly reliable
with no ﬁxation losses, false positives, or false negatives in either eye. 60-4 testing using a size V target with FASTPAC algorithm revealed no viable peripheral vision between 30 and
60 in the right (C) or left (D) eyes.
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reported in a patient with ARB [20].
Mutations in BEST1 like that observed in our subject have
been previously reported. Notably, our laboratory identiﬁed the
mutation I366fsX384 in a subject with ARB and her asymptom-
atic mother, and larger deletions have also been reported in
subjects with ARB and their asymptomatic parents [15,20,23,24].
For the Best1I366fsX384 mutation, Best1 anion channel activity is
unimpaired, and recent studies reporting on the structure of
Best1 found that the entire anion channel domain of Best1 is
contained within the region that is present in Best1 H422fsX431
[25,26]. For this reason it is unclear how the H422fsX431 mu-
tation could be solely responsible for RP in the proband despite
the fact that it is a large de novo mutation that does not occur in
either parent.
Interestingly, both parents carry heterozygous mutations in
retinal degeneration genes other than BEST1, and some of these
mutations have been passed along to the proband. Analysis of
the family carrying BEST1I366fsX384 did not reveal similarmutations in any of these genes suggesting the possibility that
they may serve as modiﬁers in our proband. Alternatively, there
may be intergenic mutations that went undetected by our
sequencing methods, and it is of course possible that other genes
we have not examined result in RP when combined with the
Best1H422fsX431 mutation. Since there is only a single proband,
this is difﬁcult to determine. However, the overlap of reported
mutations in BEST1 that segregate with both RP and BVMD in
other families suggests the possibility of a digenic or complex
genetic cause for RP in these subjects [7]. Future studies should
address identiﬁcation of other genes that may contribute to this
phenotype.Financial support
Supported by an unrestricted grant from Research to Prevent
Blindness Inc, New York, NY., and the Mayo Foundation for Medical
Research.
Fig. 5. Full-ﬁeld scotopic Ganzfeld electroretinogram (ERG) testing of both eyes (AeC) revealed attenuation of rod responses with depressed amplitudes throughout. Photopic full-
ﬁeld ERG (DeE) showed trace residual cone responses. Scotopic 0.2 cd-Sec/M2 showed diminished responses with time to 0.05 mV predicted at 29.9 years OD and 23.9 years OS.
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